Journal article
Flaw-diversion panacea or poison?
Frontiers in neurology, Vol.5, 21
01/01/2014
DOI: 10.3389/fneur.2014.00021
PMCID: PMC3938101
PMID: 24592254
Abstract
Endovascular therapy is now the treatment of choice for intracranial aneurysms (IAs) for its efficacy and safety profile. The use of flow diversion (FD) has recently expanded to cover many types of IAs in various locations. Some institutions even attempt FD as first line treatment for unruptured IAs. The most widely used devices are the pipeline embolization device (PED), the SILK flow diverter (SFD), the flow redirection endoluminal device (FRED), and Surpass. Many questions were raised regarding the long-term complications, the optimal regimen of dual antiplatelet therapy, and the durability of treatment effect. We reviewed the literature to address these questions as well as other concerns on FD when treating IAs.
Details
- Title: Subtitle
- Flaw-diversion panacea or poison?
- Creators
- Mario Zanaty - Jefferson Hospital for NeuroscienceNohra Chalouhi - Jefferson Hospital for NeuroscienceStavropoula I. Tjoumakaris - Jefferson Hospital for NeuroscienceRobert H. Rosenwasser - Jefferson Hospital for NeuroscienceL. Fernando Gonzalez - Jefferson Hospital for NeurosciencePascal Jabbour - Jefferson Hospital for Neuroscience
- Resource Type
- Journal article
- Publication Details
- Frontiers in neurology, Vol.5, 21
- DOI
- 10.3389/fneur.2014.00021
- PMID
- 24592254
- PMCID
- PMC3938101
- NLM abbreviation
- Front Neurol
- ISSN
- 1664-2295
- eISSN
- 1664-2295
- Publisher
- Frontiers Media Sa
- Number of pages
- 8
- Language
- English
- Date published
- 01/01/2014
- Academic Unit
- Iowa Neuroscience Institute; Neurosurgery
- Record Identifier
- 9984527200902771
Metrics
3 Record Views